{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:50:51Z","timestamp":1787007051716,"version":"build-2736575974"},"reference-count":165,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2022,9,2]]},"DOI":"10.1080\/13543776.2022.2116311","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T02:12:51Z","timestamp":1661134371000},"page":"1003-1026","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins"],"prefix":"10.1080","volume":"32","author":[{"given":"Pratik","family":"Pal","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saikat K.","family":"Poddar","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangrong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,9,1]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1080\/01926230701320337"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0089-8"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0901217"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgx016"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1038\/nrc776"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2015.17"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2013.733001"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2015.50"},{"issue":"14","key":"cit0009","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1111\/febs.13472","volume":"283","author":"Opfermann JT","year":"2016","journal-title":"FEBS J"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1038\/nature03579"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5836"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1021\/jm800669s"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2012.644274"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2017.1249848"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01888"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2017.06.014"},{"issue":"1","key":"cit0017","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","volume":"14","author":"Wang H","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"7","key":"cit0018","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4155\/fmc-2020-0004","volume":"12","author":"Zhang X","year":"2020","journal-title":"Future Med Chem"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00407-4"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0596-x"},{"issue":"15","key":"cit0022","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2021.39.15_suppl.3015","volume":"39","author":"Tolcher AW","year":"2021","journal-title":"J Clin Oncol"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0668-z"},{"issue":"4","key":"cit0024","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","volume":"20","author":"Mullard A","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1126\/science.3874430"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(85)80070-2"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1038\/335440a0"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2285"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-347849"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70261-8"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.6208"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7898"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.01.037"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402081"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-868752"},{"issue":"15","key":"cit0036","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1200\/JCO.2021.39.15_suppl.7502","volume":"39","author":"Ailawadhi S","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16","key":"cit0037","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1158\/1538-7445.AM2020-3077","volume":"80","author":"Hu N","year":"2020","journal-title":"Cancer Res"},{"issue":"13","key":"cit0038","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1158\/1538-7445.AM2021-1276","volume":"81","author":"Tiran AL","year":"2021","journal-title":"Cancer Res"},{"issue":"1","key":"cit0039","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1182\/blood-2021-145380","volume":"138","author":"Alencar AJ","year":"2021","journal-title":"Blood"},{"key":"cit0040","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.annonc.2021.08.1050","volume":"32","author":"Pinchman JR","year":"2021","journal-title":"Ann Oncol"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24744"},{"key":"cit0042","first-page":"125","volume":"4","author":"Saliba AN","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1119"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222588"},{"key":"cit0045","unstructured":"Wang CW, Chen J. N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors. WO2018\/027097, 2018"},{"key":"cit0046","unstructured":"Guo Y, Xue H, Wang Z, et al. Bcl-2 inhibitors. WO2019\/210828, 2019."},{"key":"cit0047","unstructured":"Hu N, Guo Y, Wang Z. Methods of cancer treatment using bcl-2 inhibitor WO2021\/110102. 2021."},{"key":"cit0048","unstructured":"Guo Y, Xue H, Wang Z, et al. Bcl-2 inhibitors. US2021\/0269433, 2021."},{"key":"cit0049","unstructured":"Xue H, Guo Y, Wang Z. Bcl-2 Inhibitors. WO2021\/083135, 2021."},{"key":"cit0050","unstructured":"Xue H, Guo Y, Wang Z. Bcl-2 inhibitor. WO2021\/208963, 2021."},{"key":"cit0051","unstructured":"Wang H, Zhu Y, Shang X, et al. BCL-2 selective inhibitor and preparation and use thereof. WO2018\/041284, 2021."},{"key":"cit0052","unstructured":"Zhuo J, Combs AP, Wei P, et al. Bcl-2 inhibitors and their use as pharmaceuticals. US2021\/0346405, 2021."},{"key":"cit0053","unstructured":"Zhang W, Liu H, Tan R, et al. Compounds as bcl-2 inhibitors. WO2021\/223736, 2021."},{"key":"cit0054","unstructured":"Fei L, Yanlong L, Hongjiang X, et al. Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective bcl-2 inhibitor. WO2020\/238785. 2020."},{"key":"cit0055","unstructured":"Yihan W, Zhiqiang L. N-benzenesulfonylbenzamide compound for inhibiting bcl-2 protein and composition and use thereof. WO2019\/001383, 2019."},{"key":"cit0056","unstructured":"Chen Y. Bcl-2 inhibitors. WO2017\/132474, 2017."},{"key":"cit0057","unstructured":"Chen Y. Bcl-2 inhibitors. WO2020\/041406, 2020."},{"key":"cit0058","unstructured":"Chen Y. Bcl-2 inhibitors. WO2020\/140005, 2020."},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100712"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1574"},{"issue":"401","key":"cit0061","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1126\/scitranslmed.aam7049","volume":"9","author":"Merino D","year":"2017","journal-title":"Sci Transl Med"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-704908"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.99"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0928"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2760"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1101\/gad.186189.111"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1038\/nature09779"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.10.006"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.3.991.991_991_1000"},{"issue":"1","key":"cit0070","first-page":"40","volume":"56","author":"L\u00f8mo J","year":"1996","journal-title":"Cancer Res"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.02.007"},{"key":"cit0072","unstructured":"Wendt MD, Shen W, Dickman DA, et al. Apoptosis promoters. WO2007\/008627. 2007."},{"issue":"6","key":"cit0073","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.bmcl.2014.02.010","volume":"24","author":"Petros AM","year":"2014","journal-title":"Bioorg Med Chem Lett"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1021\/jm501258m"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.561"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1038\/nature19830"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01660"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01155"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0140"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0387"},{"issue":"16","key":"cit0081","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1158\/1538-7445.AM2020-6218","volume":"80","author":"Caenepeel S","year":"2020","journal-title":"Cancer Res"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07551-w"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-865527"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00134"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01234"},{"issue":"13","key":"cit0086","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1158\/1538-7445.AM2021-983","volume":"81","author":"Bhagwat N","year":"2021","journal-title":"Cancer Res"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127717"},{"issue":"11","key":"cit0088","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/13543776.2019.1672661","volume":"29","author":"Fletcher S","year":"2019","journal-title":"Ther. Pat"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2017.1249848"},{"key":"cit0090","unstructured":"Kotschy A, Szl\u00e1vik Z, Cs\u00e9kei M, et al. New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them. WO2015\/097123, 2015."},{"issue":"7626","key":"cit0091","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"Szl\u00e1vik Z","year":"2016","journal-title":"Nature"},{"key":"cit0092","unstructured":"B\u00e1lint B, Cs\u00e9kei M, Szab\u00f3 Z, et al. New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them. WO2016\/207217. 2016."},{"key":"cit0093","unstructured":"Szl\u00e1vik Z, Kotschy A, Chanrion M, et al. New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. WO2016\/207225, 2016."},{"issue":"7626","key":"cit0094","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"Szl\u00e1vik Z","year":"2016","journal-title":"Nature"},{"issue":"5","key":"cit0095","doi-asserted-by":"crossref","first-page":"8892","DOI":"10.1021\/acsomega.9b00611","volume":"4","author":"Murray JB","year":"2019","journal-title":"ACS Omega"},{"key":"cit0096","unstructured":"Brady P, Braje W, Dai Y, et al. Macrocyclic MCL-1 inhibitors and methods of use. WO2019\/035899, 2019."},{"key":"cit0097","unstructured":"Braje W, Doherty G, Jantos K, et al. Macrocyclic MCL-1 inhibitors and methods of use. WO2019\/035911. 2019."},{"key":"cit0098","unstructured":"Brady P, Braje W, Dai Y, et al. Macrocyclic MCL-1 inhibitors and methods of use. WO2019\/035914, 2019."},{"key":"cit0099","unstructured":"Braje W, Doherty G, Jantos K, et al. Macrocyclic MCL-1 inhibitors and methods of use. WO2019\/035927, 2019"},{"key":"cit0100","unstructured":"Brown SP, Li Y, Lizarzaburu ME, et al. Tetrahydronaphthalene derivatives that inhibit MCL-1 protein. WO2016\/033486, 2016."},{"key":"cit0101","unstructured":"Brown SP, Bedke DK, Degraffenreid MR, et al. Compounds that inhibit MCL-1 protein. WO2017\/147410, 2017."},{"key":"cit0102","unstructured":"Harrington PE, Ashton K, Brown SP, et al. Compounds that inhibit MCL-1 protein. WO2018\/183418, 2018."},{"key":"cit0103","unstructured":"Brown SP, Harrington PE, Lanman BA, et al. Macrocyclic compounds that inhibit MCL-1 protein. WO2019\/046150. 2019."},{"key":"cit0104","unstructured":"Brown SP, Lanman BA, Li K, et al. Compounds that inhibit MCL-1 protein. WO2019\/036575. 2019."},{"key":"cit0105","unstructured":"Rescourio G, Buenrostro AG, Brown SP, et al. Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere MCL-1 protein antagonists. WO2019\/173181, 2019."},{"key":"cit0106","unstructured":"According to ClinicalTrials.gov, trial ID: NCT03465540, the reason for terminating the trial is \u201cStrategic decision given our current development of AMG 176 (a similar MCL-1 inhibitor) that is in clinic, and not because of safety concerns.\u201d"},{"key":"cit0107","unstructured":"Elmore SW, Souers AJ, Bruncko M, et al. 7-substituted indole mcl-1 inhibitors. WO2008\/131000, 2008."},{"key":"cit0108","unstructured":"Hird A, Belmonte MA, Yang W, et al. Macrocyclic mcl1 inhibitors for treating cancer. WO2017\/182625, 2017."},{"key":"cit0109","unstructured":"Stewart C, Hardy S, Stark A, et al. Synthesis of mcl-1 inhibitor. WO2018\/178227. 2018."},{"key":"cit0110","unstructured":"Packer MJ, Perkins DR, Swallow S, et al. Mcl-1 inhibitors and methods of use thereof. WO2018\/178226. 2018."},{"key":"cit0111","unstructured":"Rombouts FJR, Peschiulli A. Macrocyclic inhibitors of MCL-1, WO2020\/254471, 2020"},{"key":"cit0112","unstructured":"Rombouts FJR, Reuillon T, Peschiulli A, et al. Macrocyclic indole derivatives as inhibitors of MCL-1. WO2021\/165370, 2021."},{"key":"cit0113","unstructured":"Rombouts FJR, De Boeck BCAG. Macrocyclic indole derivatives as MCL-1 inhibitors. 2021;WO2021\/099579."},{"key":"cit0114","unstructured":"Rombouts FJR, De Boeck BCAG. Macrocyclic sulfonyl derivatives as MCL-1 inhibitors. WO2021\/099580, 2021."},{"key":"cit0115","unstructured":"Rombouts FJR, Diels GSM, Jerhaoui S, et al. Macrocyclic spirocycle derivatives as MCL-1 inhibitors. WO2021\/005043, 2021."},{"key":"cit0116","unstructured":"Chu H, Guerrero JA, Hurtley AE, et al. MCL-1 inhibitors. WO2019\/222112, 2019."},{"key":"cit0117","unstructured":"Chu H, Guerrero JA, Hurtley AE, et al. Mcl1 inhibitors. WO2021\/096860, 2021."},{"key":"cit0118","unstructured":"Tang G, Li D, Li L, et al. Macrocyclic fused pyrrazoles as MCL-1 inhibitors. WO2020\/151738. 2020."},{"key":"cit0119","unstructured":"Chen J, Zhou Y, Tang G, et al. Macrocyclic spiroethers as MCL-1 inhibitors. WO2020\/147802. 2020."},{"key":"cit0120","unstructured":"Zhuo J. 2-((5-(phenyl)-pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-3-(phenyl)propanoic acid derivatives and related compounds as MCL-1 enzyme inhibitors for treating cancer. WO2020\/123994, 2020."},{"key":"cit0121","unstructured":"Zhuo J, Leal R, Shetty R, et al. Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein. WO2020\/097577, 2020."},{"key":"cit0122","unstructured":"O\u2019boyle BM, Baker-Tripp EL, Reeves CM, et al. Mcl1 inhibitors and uses thereof. WO2021\/067827, 2021."},{"key":"cit0123","unstructured":"Zhang J, Huang PQ, Bunker KD, et al. Macrocyclic compounds. WO2020\/185606, 2020."},{"key":"cit0124","unstructured":"Zhang J, Huang PQ, Bunker KD, et al. Macrocyclic compounds. WO2021\/126316. 2021."},{"key":"cit0125","unstructured":"Hudson R, Beausoleil A-M, Kolluri R. MCL-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer. WO2021\/092053, 2021."},{"key":"cit0126","unstructured":"Zhang G, Fei H, Zhang X, et al. Indole macrocyclic derivative, preparation method therefor and application thereof in medicine. WO2020\/063792. 2020."},{"key":"cit0127","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.141230798"},{"key":"cit0128","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.211"},{"key":"cit0129","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00371-6"},{"issue":"26","key":"cit0130","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1038\/s41388-020-1336-y","volume":"39","author":"Khan S","year":"2020","journal-title":"Oncogene"},{"key":"cit0131","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2021.1840553"},{"key":"cit0132","first-page":"943648","author":"Vogler M","year":"2014","journal-title":"Adv Med"},{"issue":"21","key":"cit0133","first-page":"6101","volume":"60","author":"Amundson SA","year":"2000","journal-title":"Cancer Res"},{"key":"cit0134","doi-asserted-by":"publisher","DOI":"10.1021\/ml5001867"},{"key":"cit0135","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4642"},{"key":"cit0136","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.9b00568"},{"key":"cit0137","unstructured":"Zheng G, Zhou D, Zhang X, et al. Compounds that induce degradation of anti-apoptotic BCL-2 family proteins and the uses thereof. WO2017\/184995, 2017."},{"key":"cit0138","unstructured":"Zheng G, Zhou D, Zhang X, et al. BCL-2 proteins degraders for cancer treatment. WO2019\/144117, 2019."},{"key":"cit0139","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2020.00017"},{"key":"cit0140","doi-asserted-by":"publisher","DOI":"10.1039\/C9CC07217A"},{"key":"cit0141","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112397"},{"issue":"1","key":"cit0142","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41467-020-15838-0","volume":"11","author":"He Y","year":"2020","journal-title":"Nat Commun"},{"key":"cit0143","unstructured":"Zheng G, Zhou D, Pal P, et al. Therapeutic agents and methods of treatment. WO2020\/163823. 2020."},{"issue":"19","key":"cit0144","doi-asserted-by":"crossref","first-page":"14230","DOI":"10.1021\/acs.jmedchem.1c00517","volume":"64","author":"Pal P","year":"2021","journal-title":"J Med Chem"},{"issue":"1","key":"cit0145","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.1038\/s41467-021-27210-x","volume":"12","author":"Lv D","year":"2021","journal-title":"Nat Commun"},{"key":"cit0146","unstructured":"Zheng G, Zhou D, Zhang X, et al. Therapeutic agents and methods of treatment. WO2021\/146536145. 2021."},{"key":"cit0147","unstructured":"Pinchman JR, Bunker KD, Huang PQ. BCL-2 protein inhibitors. WO2021\/007307, 2021."},{"key":"cit0148","unstructured":"Pinchman JR, Bunker KD, Huang PQ. BCL-2 protein inhibitors. WO2021\/222114, 2021."},{"key":"cit0149","unstructured":"Yang X, Jiang B, Tan W, et al. Protein degrading agent and use thereof in treatment of diseases. WO2021\/078301, 2021."},{"issue":"3","key":"cit0150","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41419-020-03351-7","volume":"12","author":"Slomp A","year":"2021","journal-title":"Cell Death Dis"},{"issue":"25","key":"cit0151","doi-asserted-by":"crossref","first-page":"17802","DOI":"10.1074\/jbc.M114.548172","volume":"289","author":"Pang X","year":"2014","journal-title":"J Bio. Chem"},{"key":"cit0152","unstructured":"Chen Y. Condensed heterocycles as BCL-2 inhibitors. WO2021\/066873, 2021."},{"key":"cit0153","unstructured":"Voisin-Chiret A-S, Kieffer C, Guedeney G, et al. BCL-2 family proteins modulating compounds for cancer treatment. WO2021\/180966. 2021."},{"key":"cit0154","doi-asserted-by":"publisher","DOI":"10.1021\/jm500672y"},{"key":"cit0155","unstructured":"Zhang Z, Wang Z. Sulphur\/oxo naphthoyl imide compounds and its application. CN107382862, 2017."},{"key":"cit0156","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00919"},{"key":"cit0157","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0077"},{"key":"cit0158","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1283032"},{"key":"cit0159","doi-asserted-by":"publisher","DOI":"10.1101\/gad.215871.113"},{"key":"cit0160","doi-asserted-by":"publisher","DOI":"10.1101\/gad.215855.113"},{"key":"cit0161","unstructured":"Burger M, Chanrion M, Colland F, et al. MCL-1 inhibitor antibody-drug conjugates and methods of use. WO2020\/236817. 2020."},{"key":"cit0162","unstructured":"Burger M, Chanrion M, Colland F, et al. MCL-1 inhibitor antibody-drug conjugates and methods of use. WO2020\/236825. 2020."},{"key":"cit0163","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00455"},{"issue":"15","key":"cit0164","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1200\/JCO.2020.38.15_suppl.3509","volume":"38","author":"Lakhani NJ","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"cit0165","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s42003-020-01631-8","volume":"4","author":"Patterson CM","year":"2021","journal-title":"Commun Biol"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2022.2116311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T02:06:08Z","timestamp":1727834768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2022.2116311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":165,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,2]]}},"alternative-id":["10.1080\/13543776.2022.2116311"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2022.2116311","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}